Brain Cancer Research
Can Immunotherapy Succeed in Glioblastoma?Posted: May 24, 2018
Despite continued efforts to develop new therapies for glioblastoma, none have been able to improve how long patients live appreciably. Despite some setbacks, researchers are hopeful that immunotherapy might be able to succeed where other therapies have not.
Adding Immune-based Treatments to Standard Glioblastoma TherapyPosted: October 11, 2017
This phase 2 trial is testing standard therapy (surgery, radiation, and temozolomide) plus the checkpoint inhibitor pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.
Glioblastoma—Unraveling the Threads: A Q&A with Drs. Mark Gilbert and Terri Armstrong of the NIH Neuro-Oncology BranchPosted: August 3, 2017
Progress against the brain cancer glioblastoma has been slow. Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss why and what’s being done to change that.
PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH MutationsPosted: April 24, 2017
Studies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.
Brain Cancer’s Cholesterol Addiction May Offer New Treatment StrategyPosted: December 16, 2016
Brain cancer cells are heavily dependent on a constant supply of cholesterol to survive, a new study suggests. And in mice with brain tumors, treatment with a cholesterol-depleting drug slowed tumor growth and improved survival.
Trials Produce Practice-Changing Results for Brain CancerPosted: June 9, 2016
Results from two clinical trials show that treating patients with the chemotherapy drug temozolomide in addition to radiation therapy increased overall and progression-free survival.
Genome Study Links Misfolded DNA to Brain TumorsPosted: January 12, 2016
Changes in the packaging of DNA in the cell nucleus may activate growth-promoting genes that cause cancer.
Patient with Brain Tumor Responds Dramatically to Targeted TherapyPosted: December 3, 2015
A patient with a papillary craniopharyngioma saw his tumor shrink more than 80 percent after treatment with a targeted drug that inhibits a mutant form of the BRAF protein.
Genomic underpinnings of brain tumors expandedPosted: June 10, 2015
TCGA researchers analyzed nearly 300 cases of diffuse low- and intermediate-grade gliomas, which together comprise lower-grade gliomas. LGGs occur mainly in adults and include astrocytomas, oligodendrogliomas and oligoastrocytomas.
"Flipping the Switch": An Interview with Dr. Mark Gilbert, Chief of NIH’s Neuro-Oncology BranchPosted: February 18, 2015
NCI's Dr. Mark Gilbert discusses new developments in neuro-oncology and the priorities of the Neuro-Oncology Branch.
Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumorPosted: February 3, 2014
Adults with low-grade gliomas, a form of brain tumor, who received chemotherapy following completion of radiation therapy lived longer than patients who received radiation therapy alone, according to long-term follow-up results from a NIH-supported randomized controlled clinical trial. Low-grade gliomas have a more indolent or slower growing behavior and better outcome compared to the more common high-grade gliomas such as glioblastoma. [Image copyright Mayo Clinic, 2012]
Genomic understanding of glioblastoma expandedPosted: October 10, 2013
Glioblastoma multiforme (GBM) was the first cancer type to be systematically studied by TCGA in 2008. In a new, complementary report, TCGA experts examined more than 590 GBM samples--the largest to date utilizing genomic characterization techniques and nearly 400 more than were examined in 2008--to identify several additional significantly mutated genes in GBM implicated in the regulation of chromatin modification.
Video Eases End-of-Life Care DiscussionsUpdated: January 3, 2013
Patients with advanced cancer who watched a video that depicts options for end-of-life care were more certain of their end-of-life decision making than patients who only listened to a verbal narrative and were likely to choose comfort care over aggressive medical care for their end-of-life care preferences, according to an article published online November 30, 2009, in the Journal of Clinical Oncology.